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Background: We recently reported a terminal deletion of approximately 2.4 Mb at chromosome 8p23.2-pter in a
boy with autism. The deleted region contained the DLGAP2 gene that encodes the neuronal post-synaptic density
protein, discs, large (Drosophila) homolog-associated protein 2. The study aimed to investigate whether DLGAP2 is
genetically associated with autism spectrum disorders (ASD) in general.
Methods: We re-sequenced all the exons of DLGPA2 in 515 patients with ASD and 596 control subjects from
Taiwan. We also conducted bioinformatic analysis and family study of variants identified in this study.
Results: We detected nine common single nucleotide polymorphisms (SNPs) and sixteen novel missense rare
variants in this sample. We found that AA homozygotes of rs2906569 (minor allele G, alternate allele A) at intron 1
(P = 0.003) and CC homozygotes of rs2301963 (minor allele A, alternate allele C) at exon 3 (P = 0.0003) were
significantly over-represented in the patient group compared to the controls. We also found no differences in the
combined frequency of rare missense variants between the two groups. Some of these rare variants were predicted
to have an impact on the function of DLGAP2 using informatics analysis, and the family study revealed most of the
rare missense mutations in patients were inherited from their unaffected parents.
Conclusions: We detected some common and rare genetic variants of DLGAP2 that might have implication in the
pathogenesis of ASD, but they alone may not be sufficient to lead to clinical phenotypes. We suggest that further
genetic or environmental factors in affected patients may be present and determine the clinical manifestations.
Trial registration: ClinicalTrial.gov, NCT00494754
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Autism spectrum disorders (ASD) are a group of
childhood-onset neurodevelopmental disorders charac-
terized by impaired verbal/nonverbal communication,
abnormal reciprocal social interaction, and the presence
of stereotyped behaviors and restricted interests. Due to
increased awareness and clinical sensitivity to ASD,
broadening of the diagnostic criteria of ASD by includ-
ing Asperger’s disorder and Pervasive Developmental
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reproduction in any medium, provided the ordisorder, and other contributing factors, the prevalence
of ASD has increased markedly in the past decade. Re-
cent data showed that up to approximately 11 persons
per thousand in the USA are affected with ASD, and
males are more predominantly affected than females
[1-3]. The literature documents strong evidence of a
high degree of genetic influence in the etiology of autism
with high heritability estimated to be more than 90%
[4]. Genetic approaches such as cytogenetic analysis,
genome-wide linkage and association scans, and candi-
date gene analysis, have been used to dissect the genetic
complexity of ASD [5].
Traditional cytogenetic studies [6-9] and the recent
array-based comparative genomic hybridization (array
CGH) analysis have shown that chromosome abnor-
malities and rare copy number variants [10,11] aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ities such as deletion, duplication, inversion, and trans-
location were identified in ASD patients. In particular,
the advent of array CGH technology has greatly facili-
tated the detection of formerly undetectable submicro-
scopic copy number variants that are associated with
ASD [10-14].
Our group previously identified two novel chromosome
deletions in ASD using karyotyping analysis and array
CGH [15]. One was a terminal deletion of approximately
2.4 Mb at 8p23.2-pter detected in a male patient with
autistic disorder [15]. Several genes with neurobiological
functions such as discs, large (Drosophila) homolog-
associated protein 2 (DLGAP2), ceroid-lipofuscinosis, neur-
onal 8 (CLN8), the Rho guanine nucleotide exchange factor
10 (ARHGEF10) and F-box protein 25 (FBXO25), were
mapped to this region. It is likely that haploinsufficiency of
one or several of these genes might result in the clinical
phenotypes of the affected patients. Hence, these genes
might be considered as candidate genes of ASD patients in
general.
DLGAP2 (GeneID 9298) encodes the discs, large
(Drosophila) homolog-associated protein 2, which is also
called PSD-95/SAP90-binding protein 2 and SAP90/
PSD-95-associated protein 2 (SAPAP2). The protein is
one of the membrane-associated guanylate kinases local-
ized at the post-synaptic density that plays a role in the
molecular organization of synapses and in neuronal cell
signaling [16]. These kinases are a family of signaling
molecules expressed at various submembrane areas, and
contain the PDZ, SH3 and the guanylate kinase domains.
Several studies have suggested that the synapse associ-
ated proteins (SAPs) localized at postsynaptic density are
involved in the pathophysiology of psychiatric disorders
[17-21]. Marshall et al. detected 13 loci with recurrent
CNV in autism cases; they found that several postsynap-
tic density genes and synapse complex genes were
mapped in these CNVs [22]. They also found that a
genomic DNA duplication intersected the DLGAP2 gene
in a patient with autism [22]. In addition, Ozgen et al.
reported a classical inv dup del(8p) in a female patient
with autism whose DLGAP2 gene was located within the
6.9 Mb terminal deletion [23]. Together with the finding
in our previous study, these studies suggest that the
DLGAP2 gene is an important candidate gene of ASD. To
test this hypothesis, we conducted a deep resequencing of
all the exons of the DLGAP2 in a sample of ASD from
Taiwan. Herein, we present our findings of the genetic
analysis of DLGAP2 in this report.
Methods
Subjects and procedures
All subjects were Han Chinese from Taiwan. Patients
meeting the diagnostic criteria of either autistic disorderor Asperger’s disorder according to the DSM-IV and
ICD-10 were enrolled in this study from the psychiatry
department of a university hospital, a private medical
center, and schools and early intervention centers in
northern Taiwan. Subjects with ASD aged 3 to 25 years
old, and with a clinical diagnosis of ASD confirmed by
the structured interview using the Chinese version
of the Autism Diagnostic Interview-Revised (ADI-R)
[24,25]. They received clinical assessments and provided
DNA data at the university hospital, no matter whether
they were recruited from this university hospital or re-
ferred by other places. Patients with known chromo-
somal abnormalities and associated medical conditions
were excluded from the study. Subjects receiving routine
medical check-ups at the Department of Family Medi-
cine of a medical center were recruited as controls. The
mental status of the control subjects was screened by a
senior psychiatrist. Individuals with major psychiatric
disorders including ASD were excluded.
The Research Ethics Committee of the research sites
approved this study. The patients and their parents were
informed that participation in this study was completely
voluntary and that nonparticipation would not influence
their treatment. Written informed consent was obtained
from the patients if they were able to understand the
contents of the study, the parents of all the patients, and
all the control subjects after the procedures were fully
explained. A total of 515 patients with ASD were
recruited into this study, including 449 male patients
(mean age ± standard deviation (SD) = 8.9 ± 4.6 years)
and 66 female patients (mean age ± SD = 8.5 ± 4.4
years). The control group comprised 596 individuals in-
cluding 263 males (mean age ± SD = 42.5 ± 15.1 years)
and 333 females (mean age ± SD = 45.2 ± 13.4 years).
The ADI-R data of the 515 patients revealed the scores
as 21.19 ± 5.78 in the ‘qualitative abnormalities in recip-
rocal social interaction’ (cut-off = 10), 15.35 ± 4.19 in
the ‘qualitative abnormalities in communication, verbal’
(cut-off = 8), 8.58 ± 3.28 in the ‘qualitative abnormalities
in communication, nonverbal’ (cut-off = 7), and 7.14 ±
2.42 in the ‘restricted, repetitive and stereotyped patterns
of behaviors’ (cut-off = 3). All patients with ASD were
noted to have had abnormal development at or before
36 months.
Genomic DNA was prepared from peripheral blood
using the Puregene DNA purification system (Gentra
Systems Inc. Minneapolis, MI, USA) according to the
manufacturer’s instructions.
PCR amplification and sequencing
The genomic sequences of human DLGAP2 are available
from the NCBI Reference Sequence: NM_004745.3. The
human DLGAP2 comprises twelve exons that span ap-
proximately 207 kb on chromosome 8p23.2-23.3 [16];
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in Figure 1. Optimal PCR primer sequences were generated
to amplify each exon of the DLGAP2 using Primer3 (http://
bioinfo.ut.ee/primer3/). All the primer sequences, optimal
annealing temperatures and size of each amplicon are
listed in Additional file 1: Table S1. After PCR, aliquots of
PCR products were processed using a PCR Pre-
Sequencing Kit (USB, Cleveland, OH, USA) to remove re-
sidual primers and dNTPs following the manufacturer’s
protocol. The purified PCR products were subjected toFigure 1 (A) Schematic genomic structure of the DLGAP2, and locatio
rare variants identified in this study. (B) Linkage disequlibrium (LD) anadirect sequencing using the ABI Prism™ BigDye™ Termin-
ator Cycle Sequencing Ready Reaction Kit Version 3.1, and
the ABI autosequencer 3730 (Perkin Elmer Applied
Biosystems, Foster City, CA, USA), according to the manu-
facturer’s protocol. The quality of the sequencing results
was visualized using Chromas 2.4.1 software (Technelysium
Pty Ltd, South Brisbane, Australia). For variant identifica-
tion, sequencing results of each subject were aligned and
compared with the reference sequences using BioEdit soft-
ware (http://www.mbio.ncsu.edu/bioedit/bioedit.html). Tons of the common single nucleotide polymorphisms (SNPs) and
lysis of nine common SNPs identified in this study.
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repeated PCR from genomic DNA and re-sequencing of
the amplicon in both directions were performed. The
nomenclature of genetic variants follows the rules of the
‘Nomenclature for description of human sequence varia-
tions’ [26].
Statistical analysis
For the common single nucleotide polymorphisms
(SNPs), the differences in the allele and genotype fre-
quencies between the patients and controls were
assessed with the Chi-square test. Fisher's exact test was
used to compare the combined frequency of rare vari-
ants between the patient and the control groups. It was
also used to compare the frequency of damaging and
functional rare missense variants between the ASD and
control groups. Assessment of haplotype-based associ-
ation analyses was performed using the SHEsis com-
puter program [27]. A P value of less than 0.05 was
considered statistically significant, and Bonferroni
correction for multiple comparisons was performed
when appropriate. We also calculated the Q value
for each test with the false discovery test of 5%
using QVALUE software (http://genomics.princeton.
edu/storeylab/qvalue/) [28].
Results
After sequencing all the exons of DLGAP2 in 515 pa-
tients and 596 control subjects, we identified nine com-
mon SNPs (defined as with a minor allele frequency >
0.05), and a total of 49 rare variants (defined as with a
frequency < 0.05) in this sample. The locations of these
variants are listed in Figure 1.
Case-control association study of common SNPs
The genotype and allele frequencies of nine common
variants in the patients and control subjects are listed in
Table 1. Two SNPs (rs2906569 and rs2301963) were
found to have significant differences in genotype fre-
quency distribution between the patient and control
groups, even after correction for multiple comparisons.
The rs2906569 (A > G) was located at intron 1. The
genotype AA homozygotes (G: minor allele, A: alternate
allele) were significantly over-represented in the patient
group compared to the control group (odds ratio: 1.46;
95% confidence interval, 1.13 to 1.87, P = 0.003)
(Table 2). When the subjects were sub-grouped by gen-
der, the over-representation of genotype AA homozy-
gotes was still observed in male patients but not in
female patients (Table 2). The rs2301963 (C > A) was a
missense variant (P384Q) located at exon 3 (A: minor
allele, C: alternate allele). The CC homozygotes were
significantly over-represented in the patient group com-
pared to the control group (odds ratio: 1.30; 95%confidence interval, 0.99 to 1.70; P = 0.0003) (Table 2).
When the subjects were sub-grouped by gender, the
over-representation of CC homozygotes was observed in
male patients but not in female patients (Table 2).
Further linkage disequilibrium (LD) analysis showed
strong LD among rs6996621, rs2906568, rs2906569,
and rs60089073. In addition, rs2235112 and rs2235113
also showed strong LD (Figure 1). In haplotype-based
association analysis derived from nine SNPs, we found
significant difference in the haplotype distribution of
ACACAAGGT and CCACCAACT between the ASD
patients and controls, but only haplotype CCA
CCAACT was sustained after correction for multiple
comparisons (Table 3).Identification of rare genetic variants of DLGAP2
In this study, we found a total of 16 rare missense muta-
tions in our ASD patients and control subjects. The lo-
cations of these variants are illustrated in Figure 1.
These missense variants are novel and have not been
reported before in the literature. Distributions of these
rare missense variants are listed in Table 4. There was
no significant difference in the combined frequency of
rare missense mutations between the two groups (P =
1.00). Those individuals who carried these rare missense
mutations had only one missense mutation; we found
no individual who carried two rare missense variants
simultaneously.Family study and functional prediction of rare variants
A total of 10 missense variants (S15F, R93S, R182Q,
A192S, P281A, R324W, C506R, T712M, E798Q and
P917L) were detected in 13 patients (Table 4). All the
patients carrying these rare variants were heterozygotes.
Four of the 13 patients (A, B, J, K) inherited the variant
from their mothers and 6 (C, D, E, F, G, H) from their
fathers (Figure 2). Three patients did not have enough
genetic information from the parents. Among these ten
missense variants, seven (S15F, R93S, R182Q, A192S,
R324W, C506R and E798Q were found in the patient
group only, while the other three (P281A, T712M and
P917L) were detected also in the control group. Aside
from these three variants that overlapped with the pa-
tient group, six missense variants (V234L, A421V,
P771A, H796D, D884N, and N892K) were unique in the
control group. The inheritance mode of missense vari-
ants found in the control group cannot be traced be-
cause we did not collect their parents’ DNA. In the
analysis of functional prediction of these 16 rare mis-
sense variants, S15F, R93S, R182Q, P281A, R324W,
C506R, H796D, E798Q, and N892K were predicted to
have functional impact on the protein using the
PolyPhen-2 or SIFT computer program (Table 4).
Table 1 Allele and genotype frequencies of common SNPs of the DLGAP2 gene in ASD patients and control subjects (MAF > 5%)
SNP Location Diagnosis n Genotype P value Q value Allele P value Q value Odds ratio (95 % CI)
rs6996621 intron 1 C/C C/A A/A C A C versus A
c.-68-61C > A total autism 454 387 (85.2%) 62 (13.7%) 5 (1.1%) 0.619 0.312 836 (92.1%) 72 (7.9%) 0.401 0.204 1.11 (0.83 to 1.57)
control 557 467 (83.8%) 80 (14.4%) 10 (1.8%) 1014 (91.0%) 100 (9.0%)
male autism 394 336 (85.3%) 55 (14.0%) 3 (0.7%) 0.593 0.203 727 (92.3%) 61 (7.7%) 0.611 0.611
control 246 208 (84.6%) 34 (13.8%) 4 (1.6%) 450 (91.5%) 42 (8.5%)
female autism 60 51 (85%) 7 (11.7%) 2 (3.3%) 0.663 0.266 109 (90.8%) 11 (9.2%) 0.956 0.956
control 311 259 (83.3%) 46 (14.8%) 6 (1.9%) 564 (90.7%) 58 (9.3%)
rs2906568 intron 1 C/C C/G G/G C G C versus G
c.-68-25C > G total autism 456 188 (41.2%) 169 (37.1%) 99 (21.7%) 0.142 0.112 545 (59.8%) 367 (40.2%) 0.125 0.105 1.15 (0.96 to 1.37)
control 557 197 (35.4%) 234 (42.0%) 126 (22.6%) 628 (56.4%) 486 (43.6%)
male autism 396 171 (43.2%) 138 (34.8%) 87 (22.0%) 0.072 0.107 480 (60.6%) 312 (39.4%) 0.146 0.299
control 246 86 (35.0%) 106 (43.0%) 54(22.0%) 278 (56.5%) 214 (43.5%)
female autism 60 17 (28.3%) 31 (51.7%) 12 (20%) 0.316 0.266 65 (54.2%) 55 (45.8%) 0.671 0.897
control 311 111 (35.7%) 128 (41.1%) 72 (23.2%) 350 (56.3%) 272 (43.7%)
rs2906569 intron 1 A/A A/G G/G A G A versus G
c.-68-4A > G total autism 458 219 (47.8%) 138 (30.1%) 101 (22.1%) 0.0006 0.095 576 (62.9%) 340 (37.1%) 0.112 0.105 1.16 (0.97 to 1.38)
control 557 215 (38.6%) 232 (41.7%) 110 (19.7%) 662 (59.4%) 452 (40.6%)
male autism 398 199 (50.0%) 109 (27.4%) 90 (22.6%) 0.0001 0.107 507 (63.7%) 289 (36.3%) 0.075 0.299
control 246 91 (37.0%) 107 (43.5%) 48 (19.5%) 289 (58.7%) 203 (41.3%)
female autism 60 20 (33.3%) 29 (48.3%) 11 (18.4%) 0.491 0.266 69 (57.5%) 51 (42.5%) 0.614 0.897
control 311 124 (39.9%) 125 (40.2%) 62 (19.9%) 373 (60.0%) 249 (40.0%)
rs60089073 exon 2 C/C C/T T/T C T C versus T
His73 total autism 466 401 (86.1%) 54 (11.6%) 11 (2.3%) 0.989 0.388 856 (91.8%) 76 (8.2%) 0.891 0.363 0.98 (0.71 to 1.35)
control 557 481 (86.4%) 63 (11.3%) 13 (2.3%) 1025 (92.0%) 89 (8.0%)
male autism 404 346 (85.6%) 48 (11.9%) 10 (2.5%) 0.236 0.133 740 (91.6%) 68 (8.4%) 0.093 0.299
control 246 219 (89.0%) 25 (10.2%) 2 (0.8%) 463 (94.1%) 29 (5.9%)
female autism 62 55 (88.7%) 6 (9.7%) 1 (1.6%) 0.607 0.266 116 (93.5%) 8 (6.5%) 0.259 0.897
control 311 262 (84.3%) 38 (12.2%) 11 (3.5%) 562 (90.4%) 60 (9.6%)
rs2301963 exon 3 C/C C/A A/A C A C versus A
Pro384Gln total autism 513 171 (33.3%) 231 (45.1%) 111 (21.6%) 0.0005 0.095 573 (55.8%) 453 (44.2%) 0.026 0.105 1.21 (1.02 to 1.43)
control 593 139 (23.4%) 328 (55.%) 126 (21.2%) 606 (51.1%) 580 (48.9%)




















Table 1 Allele and genotype frequencies of common SNPs of the DLGAP2 gene in ASD patients and control subjects (MAF > 5%) (Continued)
control 260 66 (25.4%) 136 (52.3%) 58 (22.3%) 268 (51.5%) 252 (48.5%)
female autism 65 21 (32.3%) 29 (44.6%) 15 (23.1%) 0.124 0.266 71 (54.6%) 59 (45.4%) 0.420 0.897
control 333 73 (21.9%) 192 (57.7%) 68 (20.4%) 338 (50.8%) 328 (49.2%)
rs6995760 intron 5 A/A A/G G/G A G A versus G
c.1570 + 14A > G total autism 500 346 (69.2%) 141 (28.2%) 13 (2.6%) 0.913 0.388 833 (83.3%) 167 (16.7%) 0.925 0.363 1.01 (0.80 to 1.27)
control 531 368 (69.3%) 147 (27.7%) 16 (3.0%) 883 (83.1%) 179 (16.9%)
male autism 432 305 (70.6%) 115 (26.6%) 12 (2.8%) 0.502 0.193 725 (83.9%) 139 (16.1%) 0.245 0.299
control 234 155 (66.3%) 71 (30.3%) 8 (3.4%) 381 (81.4%) 87 (18.6%)
female autism 68 41 (60.3%) 26 (38.2%) 1 (1.5%) 0.103 0.266 108 (79.4%) 28 (20.6%) 0.148 0.897
control 297 213 (71.7%) 76 (25.6%) 8 (2.7%) 502 (84.5%) 92 (15.5%)
rs2235112 exon 6 A/A A/G G/G A G A versus G
Glu598 total autism 509 95 (18.8%) 233 (45.7%) 181 (35.5%) 0.028 0.095 424 (41.6%) 595 (58.4%) 0.012 0.105 1.29 (1.05 to 1.50)
control 513 66 (12.9%) 239 (46.6%) 208 (40.5%) 371 (36.2%) 655 (63.8%)
male autism 444 85 (19.1%) 205 (46.2%) 154 (34.7%) 0.049 0.107 375 (42.2%) 513 (57.8%) 0.014 0.299
control 224 28 (12.5%) 102 (45.5%) 94 (42.0%) 158 (35.3%) 290 (64.7%)
female autism 66 11 (16.7%) 28 (42.4%) 27 (40.9%) 0.671 0.266 50 (37.9%) 82 (62.1%) 0.825 0.928
control 289 38 (13.2%) 137 (47.4%) 114 (39.4%) 213 (36.9%) 365 (63.1%)
rs2235113 intron 6 C/C C/G G/G C G C versus G
c.1920 + 19C > G total autism 510 156 (30.6%) 233 (45.7%) 121 (23.7%) 0.050 0.095 545 (53.4%) 475 (46.6%) 0.030 0.105 1.21 (1.02 to 1.44)
control 509 121 (23.8%) 253 (49.7%) 135 (26.5%) 495 (48.6%) 523 (51.4%)
male autism 443 137 (30.9%) 205 (46.3%) 101 (22.8%) 0.303 0.139 479 (54.1%) 407 (45.9%) 0.243 0.299
control 222 56 (25.2%) 113 (50.9%) 53 (23.9%) 225 (50.7%) 219 (49.3%)
female autism 67 19 (28.3%) 28 (41.8%) 20 (29.9%) 0.513 0.266 66 (49.3%) 68 (50.7%) 0.644 0.897
control 287 65 (22.6%) 140 (48.8%) 82 (28.6%) 270 (47.0%) 304 (53.0%)
rs2293909 intron 11 T/T T/C C/C T C T versus C
c.2709 + 71T > C total autism 460 255 (55.4%) 166 (36.1%) 39 (8.5%) 0.012 0.095 676 (73.5%) 244 (26.5%) 0.012 0.105 1.28 (1.06 to 1.55)
control 573 265 (46.2%) 254 (44.3%) 54 (9.4%) 784 (68.4%) 362 (31.6%)
male autism 403 230 (57.1%) 138 (34.2%) 35 (8.7%) 0.117 0.107 598 (74.2%) 208 (25.8%) 0.165 0.299
control 256 127 (49.6%) 108 (42.2%) 21 (8.2%) 362 (70.7%) 150 (29.3%)
female autism 57 25 (43.9%) 28 (49.1%) 4 (7.0%) 0.719 0.266 78 (68.4%) 36 (31.6%) 0.698 0.897
control 317 138 (43.5%) 146 (46.1%) 33 (10.4%) 422 (66.6%) 212 (33.4%)




















Table 2 Odds ratio of rs2906569 and rs2301963 of the DLGAP2 gene in patients with autism and control subjects
SNP Location Diagnosis n Odds ratio (95% CI) P value
rs2906569 intron 1 total A/A versus A/G + G/G
autism 458 1.46 (1.13 to1.87) 0.003a
control 557
male autism 398 1.70 (1.23 to 2.36) 0.001a
control 246
female autism 60 0.75 (0.42 to 1.35) 0.341
control 311
rs2301963 exon 3 total C/C versus C/A + A/A P value
autism 513 1.63 (1.25 to 2.13) 0.0003a
control 593
male autism 448 1.48 (1.05 to 2.08) 0.024a
control 260
female autism 65 1.70 (0.95 to 3.04) 0.071
control 333
aP value < 0.05; SNP, single nucleotide polymorphism.
Chien et al. Molecular Autism 2013, 4:26 Page 7 of 12
http://www.molecularautism.com/content/4/1/26The ADI-R data of these 13 patients revealed scores of
22.82 ± 7.15 (range, 8 to 28) in the ‘qualitative abnor-
malities in reciprocal social interaction’ (cut-off = 10),
15.00 ± 4.84 (range, 5 to 22) in the ‘qualitative abnor-
malities in communication, verbal’ (cut-off = 8), 9.55 ±
4.39 (range, 4 to 14) in the ‘qualitative abnormalities in
communication, nonverbal’ (cut-off = 7), and 6.00 ± 2.68
(range, 1 to 12) in the ‘restricted, repetitive and stereo-
typed patterns of behaviors’ (cut-off = 3). The average
age at which the 13 patients said their first word was
37.1 ± 17.4 (range, 15 to 66) months old and at which
they said their first phrase was 44.8 ± 18.5 (range, 19 to
78) months. Their current average intelligence quotients
(IQ) were 82.8 ± 34.0 (range 40 to 126) for full-scale IQ,
84.9 ± 32.1 (range, 41 to 123) for performance IQ, and
82.3 ± 33.1 (range, 44 to 122 ) for verbal IQ, as assessedTable 3 The distributions of haplotypes in ASD and controls
Haplotype Cases (frequency) Controls (frequenc
1 A C A C A A G G T 8.84 (0.012) 28.20 (0.036)
2 C C A C C A A C C 41.17 (0.057) 63.13 (0.080)
3 C C A C C A A C T 84.15 (0.117) 60.19 (0.076)
4 C C A C C A G G C 12.99 (0.018) 26.04 (0.033)
5 C C A C C A G G T 86.66 (0.121) 89.80 (0.114)
6 C C A T C A A C T 27.74 (0.039) 25.95 (0.033)
7 C G G C A A A C T 31.96 (0.045) 32.97 (0.042)
8 C G G C A A G G C 30.14 (0.042) 45.29 (0.057)
9 C G G C A A G G T 60.91 (0.085) 81.38 (0.103)
10 C G G C A G G C T 19.59 (0.027) 37.66 (0.048)
ASD, autistic spectrum disorders; Global result: total control = 788.0, total case = 71
case has been dropped). Fisher's P value is 0.001537. Pearson's P value is 0.001507.by the Wechsler Intelligence Scale for Children-third
edition. Due to the lack of psychometric data for the
control subjects who carried the rare missense muta-
tions, we were not able to determine their clinical
characteristics.
Clinical assessments of the parents of the 10 patients
carrying rare missense mutations found that none of
them achieved the clinical diagnosis of ASD. Their re-
ports on the Chinese version of the Autism Spectrum
Quotient [29] also revealed no evidence of an overt aut-
istic trait.
Discussion
In this study, we found that rs2906569 at intron 1 and
rs2301963 (P384Q) at exon 3 of DLGAP2 were associ-
ated with ASD. These two SNPs did not form significanty) Chi2 Fisher's P Pearson's P Odds ratio (95%CI)
7.081 0.007814a 0.007806a 0.367 (0.170 to 0.790)
1.548 0.213443 0.213365 0.768 (0.506 to 1.165)
11.981 0.000542a 0.000541a 1.880 (1.310 to 2.698)
2.331 0.126865 0.126793 0.592 (0.300 to 1.168)
1.380 0.240147 0.240071 1.218 (0.876 to 1.694)
0.973 0.324045 0.323985 1.319 (0.759 to 2.292)
0.465 0.495147 0.495131 1.192 (0.719 to 1.976)
0.902 0.342270 0.342214 0.792 (0.490 to 1.282)
0.381 0.537097 0.537090 0.892 (0.622 to 1.281)
2.960 0.085418 0.085359 0.613 (0.349 to 1.076)
8.0; global chi2 is 26.804893 while df = 9 (frequency < 0.03 in both control and
Note: aP ≤ value 0.05.
Table 4 Unique nonsynonymous variants of the DLGAP2 gene identified in ASD patients and controls and their
functional predictions
Location In silico analysis
Nucleotide position Variants PolyPhen-2 SIFT Autism Control rs2906569 rs2301963
exon2 c.44 C > T S15F probably damaging affect protein function U1974 A/A C/A
c.277 C > A R93S probably damaging tolerated U1843 A/G C/A
c.545 G > A R182Q probably damaging tolerated U173 A/G C/A
c.574 G > T A192S benign tolerated U396 A/A C/C
c.797 G > T V234L benign tolerated ZN4215 G/G C/C
c.797 G > T V234L benign tolerated HN616 A/A C/A
c.841 C > G P281A probably damaging tolerated U323 A/G C/A
c.841 C > G P281A probably damaging tolerated U1519 G/G A/A
c.841 C > G P281A probably damaging tolerated U1988 G/G C/A
c.841 C > G P281A probably damaging tolerated ZN4014 A/G missing
c.841 C > G P281A probably damaging tolerated HN449 A/G C/A
c.841 C > G P281A probably damaging tolerated HN581 A/G C/A
c.970 A > T R324W probably damaging affect protein function U1803 A/A C/A
exon4 c.1262 C > T A421V benign tolerated ZN4205 G/G A/A
exon5 c.1516 T > C C506R probably damaging affect protein function U1247 missing C/A
exon9 c.2135 C > T T712M benign tolerated U2096 G/G C/A
c.2135 C > T T712M benign tolerated HN576 missing C/A
c.2135 C > T T712M benign tolerated HN278 A/A C/A
c.2311 C > G P771A benign tolerated ZN4182 A/A C/C
c.2386 C > G H796D probably damaging affect protein function ZN4053 A/G C/A
c.2392 G > C E798Q probably damaging affect protein function U1082 A/A C/C
exon11 c.2650 G > A D884N benign tolerated HN526 G/G C/A
c.2676 C > A N892K possibly damaging affect protein function ZN4107 missing missing
exon12 c.2750 C > T P917L benign tolerated U1000 A/G C/A
c.2750 C > T P917L benign (0.002) tolerated U2098 G/G C/A
c.2750 C > T P917L benign (0.002) tolerated HN444 A/A C/C
PolyPhen-2 autism control P (Fisher’s test) SIFT autism control P (Fisher’s test)
damaging 9 5 0.12 functional 4 2 0.32
benign 4 8 tolerated 9 11
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http://www.molecularautism.com/content/4/1/26LD in our genetic analysis. The functional significance of
rs2906569 was difficult to infer, because it was located at
intron 1. As to rs2301963 (C > A, P384Q), the A allele
(Q allele) was the minor allele in our population, and
was predicted to be probably damaging using the
PolyPhen-2 computer program, but tolerated by SIFT.
Based on the finding of significant over-representation
of the CC homozygotes in the patient group, we suggest
that the Q384 variant of the DLGAP2 might confer an
increased risk of ASD, but the real mechanism and
meaning of this association remain to be clarified. The
small sample size of this study may have led to a false
positive, which is also a limitation of this study. In a re-
cent review of the role of common variants in autism,Devlin and colleagues reported their study on three large
genome-wide association (GWA) studies of autism, each
of which showed a single, non-overlapping risk locus.
They found that there was no significant finding when
all the data were combined. In their analysis, they found
no definitive, replicated results, and they could not be
certain that there was a role for common variants in aut-
ism risk [30]. Hence, an independent replication study is
needed to verify our finding.
We also detected a total of 16 novel missense rare var-
iants in the patient and control groups in this study.
Given that some of these missense mutations were pre-
dicted to have functional impact on DLGAP2, we found










































































































Figure 2 (A) Pedigree of S15F mutation, (B) Pedigree of R93S mutation, (C) Pedigree of R182Q mutation. (D) Pedigree of A192S mutation.
(E,F) Pedigrees of P281A mutation. (G) Pedigree of R324W mutation. (H) Pedigree of C506R mutation. (I) Pedigree of T712M mutation. (J) Pedigree of
E798Q mutation. (K) Pedigree of P917L mutation.
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mutations found in the patients were inherited from
their unaffected parents. Hence, the clinical relevance of
these rare missense mutations to ASD is not straightfor-
ward, and needs further elucidation.
We attempted to assess the interactions between
rs2906569 and rs2301963 and the missense rare variants
in this study, but could not detect interactions between
them. The small sample size of this study might be a
major limiting factor. There were eight AA homozygotes
of rs2906569 carrying rare missense variants, including
four patients and four controls, and there were five CC
homozygotes of rs2301963 carrying rare missense vari-
ants, including two patients and three controls. The
genotype of rs2906569 and rs2301963 in subjects carry-
ing the rare missense variants are listed in the Table 4.
To assess the phenotypic significance of two common
SNPs associated with ASD, we compared the three core
symptoms of ASD measured by the ADI-R and the
Chinese version of Social Communication Questionnaire
(SCQ) between patients with A/A and patients with
A/G + G/G of rs2906569 (Additional file 2: Table S2),
between patients with C/C and patients with C/A + A/A
of rs2301963 (Additional file 3: Table S3). We alsocompared the three core symptoms of ASD measured by
the ADI-R and SCQ between patients who carried rare
missense mutations and those did not carry rare mis-
sense mutations (Additional file 4: Table S4). The
Chinese SCQ is a screening tool based on the Autism
Diagnostic Interview-Revised (ADI-R) algorithm which
corresponds to DSM-IV diagnostic criteria. It examines
the three functional domains of reciprocal social inter-
action, communication, and restricted, repetitive, and
stereotyped patterns. The Chinese SCQ was translated
under the approval of Western Psychological Services
and was validated by the research group led by Gau and
Wu [31]. The results showed that there were no statis-
tical significant differences in all the comparisons
(all P values > 0.1), regardless of gender with the follow-
ing two exceptions. Patients with A/A of rs2906569 had
less severe social interaction impairment than patients
with A/G + G/G of rs2906569 (P = 0.0219) and such sig-
nificant difference was only noted in male patients
(P = 0.0285). But, the statistical significance did not sus-
tain after correcting for multiple testing.
ASD is a complex disease with highly heterogeneous
genetic underpinnings, and genotype-phenotype correl-
ation remains a challenging task. According to the
Chien et al. Molecular Autism 2013, 4:26 Page 10 of 12
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orders, the effect size of common variants is usually con-
sidered small or modest. Moreover, it is not unusual to
find inconsistent results among different studies, and the
common variants can only explain a small proportion of
the clinical variance. In a recent report on stage two of
the autism genome project genome-wide association
study, Anney and colleagues found that no single SNP
showed a significant association with ASD or selected
phenotypes at a genome-wide level after genotyping over
a million SNPs, and the clinical variance explained by
common variants en masse was small [32].
In contrast, the ‘rare variant hypothesis’ of complex
psychiatric disorders suggests that rare variants are likely
to have large effect sizes and to be de novo in their
origin [33]. Given that several studies have provided evi-
dence to support the large effect size of de novo rare
mutations associated with ASD [34-36], emerging evi-
dence suggests the multiple-hits model may be more ap-
propriate to explain the incomplete penetrance and
varied expressivity of genetic underpinnings of ASD
[37,38]. Girirajan and colleagues proposed a ‘two-hit’
model in which a first hit may act in concert with some
factors as a second hit, such as mutations in a single
gene, micro-deletions/duplications, epigenetic factors, or
environmental insults, and result in variable expressivity
of phenotypes in complex neuropsychiatric disorders
[38]. Furthermore, in a genetic study of high-functioning,
idiopathic ASD, Schaaf and colleagues reported that in
addition to de novo rare mutations, patients with ASD
had a significantly higher proportion of multiple events
of oligogenic heterozygosity than control subjects,
suggesting oligogenic heterozygosity is a new potential
mechanism in the pathogenesis of ASD [39]. In our pre-
vious study, we also reported a boy with ASD who car-
ried two CNVs that were inherited respectively from his
unaffected parents [40]. Our previous case report also
lent support to the two-hit and compound heterozygos-
ity models of ASD.
In a recent study examining the patterns and rates of
exonic de novo mutations in ASD, Neale and colleagues
found only a small increase in the rate of de novo events
in ASD. They suggested an important but limited role
for de novo point mutations in ASD, and supported
polygenic models of ASD [41]. In the present study, we
found that the putative deleterious missense variants
occurred in both patient and control groups with equal
chance, and that most of the rare missense mutations
were inherited from their unaffected parents. We sug-
gest that the missense mutations of DLGAP2 alone may
not be sufficient for the clinical presentations of ASD,
and additional hits such as environmental insults or fur-
ther genetic mutations in the affected patients may be
needed for the clinical presentations, which supportASD as likely a multifactorial disease. Hence, it is diffi-
cult to find a strong association with a single gene, like
DLGAP2 in this study.Conclusions
We identified two common SNPs and some rare mis-
sense mutations of DLGAP2 that might be implicated
in the pathogenesis of ASD. However, their clinical rele-
vance is not straightforward. We suggest additional gen-
etic or environmental factors in the affected patients
might be present to determine the clinical presentations.
The findings from this study can only be considered as
preliminary as it has only a limited sample size. Further
independent replication studies are needed to verify our
findings in the present study.Additional files
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